Biology subjects

Hainaut, P.

Publications and source records attributed to Hainaut, P..

3 recordsLinked to original sources

bioRxiv2025

Transfer Learning for Survival-based Clustering of Predictors with an Application to TP53 Mutation Annotation

TP53 is the most frequently mutated gene in human cancers, and germline mutations in TP53 cause Li-Fraumeni syndrome (LFS), a hereditary predisposition to diverse cancers. Accurate annotation of TP53 mutations based on their survival effects is critical for informed LFS patient management. Motivated by this need, we develop a new approach for Survival-based Clustering of Predictors (SCP) by identifying homogeneous coefficients in Cox regression. We formulate this task as a fusionpenalized Cox regression problem and provide an efficient computational algorithm. A nonconvex distance-to-set penalty is adopted to facilitate parameter tuning and improve estimation accuracy. To overcome data limitations, we further develop TLSCP, a transfer learning extension that borrows coefficient ranking information from a source dataset under the assumption of similar ranking patterns between source and target. TL-SCP integrates ranking information through weighted rank averaging, allowing flexibility in accommodating cohort heterogeneity while maintaining model simplicity. Simulation studies demonstrate TL-SCPs superior performance over SCP in clustering recovery and coefficient estimation. In the application of TP53 mutation annotation where we utilize non-LFS germline TP53 mutation carriers as a source cohort for the target LFS cohort, TL-SCP identifies biologically meaningful TP53 mutation clusters and offers improved clinical interpretability compared to experiment-based annotations.

genetics↗

bioRxiv2025

The metabolic kinase LKB1 shapes the enteric nervous system bymitigating the oxidative stress and p53 activity

The enteric nervous system (ENS) comprises ganglia of neurons and glial cells derived from migratory multipotent neural crest cells. While the molecular mechanisms of ENS development are well-studied, the involvement of metabolic processes has received less attention. We previously showed that the tumor suppressor kinase LKB1 is essential for the trophic maintenance of postnatal ENS. Here we examined LKB1s role in ENS formation using a genetically engineered mouse model that conditionally inactivates Lkb1 in neural crest progenitors during gut invasion. We conducted a comprehensive phenotyping of the ENS through histology and 3D imaging of cleared tissue, combining lightsheet microscopy with adaptive optics confocal microscopy. We found that Lkb1 loss impairs early neuronal differentiation, followed by glial degeneration, leading to hypoganglionosis and compromised digestive tissue integrity. Metabolite profiling of digestive tracts revealed an increase of oxidative stress upon Lkb1 ablation. In vitro, Lkb1 knockdown induced oxidative stress in neural crest progenitors and their glial derivatives, causing DNA damage and p53 activation. Ablation of p53 rescued glial specification under these conditions. In vivo, hyperphosphorylation of p53 was also observed; however, deletion of p53 alleles in Lkb1 mutants did not restore enteric neurons number. Instead, it improved axonal fiber organization and partially rescued digestive tissue integrity. These findings establish LKB1 as a key metabolic regulator on both the development and maintenance of the ENS, suggesting that aberrant LKB1 signaling may contribute to human enteric glioneuropathies. HighlightsO_LILKB1 loss in enteric progenitors results in extensive hypoganglionosis and disrupts gut tissue homeostasis. C_LIO_LIDuring embryogenesis, LKB1 shapes enteric ganglia by sequentially regulating neuronal differentiation and preserving glial cells, partly by limiting oxidative stress and p53 activity. C_LIO_LIThese findings establish LKB1 as a critical regulator of neural crest cell formation, highlighting its multifaceted roles and potential pathological implications in digestive neuropathies. C_LI

developmental biology↗

bioRxiv2023

Cytoskeleton remodeling induced by SMYD2 methyltransferase drives breast cancer metastasis

Malignant forms of breast cancer refractory to existing therapies remain a major unmet health issue, primarily due to metastatic spread. A better understanding of the mechanisms at play will provide better insights for alternative treatments to prevent breast cancer cells dispersion. Here, we identify the lysine methyltransferase SMYD2 as a clinically actionable master regulator of breast cancer metastasis. While SMYD2 is overexpressed in aggressive breast cancers, we notice that it is not required for primary tumor growth. However, mammary-epithelium specific SMYD2 ablation increases mouse overall survival by blocking the primary tumor cells ability to metastasize. Mechanistically, we identify BCAR3 as a genuine physiological substrate of SMYD2 in breast cancer cells. BCAR3 monomethylated at lysine K334 (K334me1) is recognized by a novel methyl-binding domain present in FMNLs proteins. These actin cytoskeleton regulators are recruited at the cell edges by the SMYD2 methylation signaling and modulates lamellipodia properties. Breast cancer cells with impaired BCAR3 methylation loose migration and invasiveness capacity in vitro and are ineffective in promoting metastases in vivo. Remarkably, SMYD2 pharmacologic inhibition efficiently impairs the metastatic spread of breast cancer cells, PDX and aggressive mammary tumors from genetically engineered mice. This study provides a rationale for innovative therapeutic prevention of malignant breast cancer metastatic progression by targeting the SMYD2-BCAR3-FMNL axis.

cancer biology↗